Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis

David C. Mohr*, Donald E. Goodkin, Lorianne Masuoka, Leah P. Dick, David Russo, Jannelle Eckhardt, Arne C. Boudewyn, Lisa Bedell

*Corresponding author for this work

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

The purpose of this study was to examine the relationship between patient management strategies employed by study personnel, and patient retention and adherence to treatment in the first year of a Phase III clinical trial of interferon beta-1b for treatment of secondary progressive multiple sclerosis (MS). Study staff from each of 35 sites were interviewed regarding patient management practices. Sites which were rated as more empathetic, as instilling a sense of purpose in the patient and promoting less formal relationships with patients had high rates of adherence to treatment. In addressing specific patient concerns, attention to patients' emotional status and patients' expectations of trial participation were related to better adherence.

Original languageEnglish (US)
Pages (from-to)192-197
Number of pages6
JournalMultiple Sclerosis
Volume5
Issue number3
DOIs
StatePublished - Jun 1999

Keywords

  • Adherence
  • Clinical trials
  • Compliance
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this